Ovid Therapeutics And Graviton Bioscience Announces Topline Data From Phase 1 Clinical Trial Studying OV888/GV101 Capsule For Cerebral Cavernous Malformations
Portfolio Pulse from Benzinga Newsdesk
Ovid Therapeutics and Graviton Bioscience announced positive topline data from their Phase 1 clinical trial of OV888/GV101 capsule for cerebral cavernous malformations. The study met its objectives, showing a favorable safety profile and achieving the target pharmacokinetic profile. A Phase 2 study is expected to start in the second half of 2024.
July 01, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ovid Therapeutics announced positive Phase 1 trial results for OV888/GV101 capsule, showing safety and target pharmacokinetic profile. Phase 2 study to start in H2 2024.
The positive Phase 1 results and the planned Phase 2 study are likely to boost investor confidence in Ovid Therapeutics, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100